Research/nci-role/cancer-centers/find/moffitt
 |
Moffitt Cancer Center
12902 Magnolia Drive MCC-CEO Tampa, Florida 33612 Main: (813) 745-4673 New Patient/Physician Referral: 1-888-860-2778 |
Moffitt Cancer Center opened in 1986 on the campus of the University of South Florida in Tampa, which was followed by active research effort beginning in 1994. Moffitt achieved NCI cancer center designation four years later (1998), and ultimately was awarded the prestigious NCI comprehensive cancer center designation in 2001.
Moffitt strives to be a leader in understanding the complexity of cancer through team science and applying those insights for human benefit. The institution employs over 800 research faculty scientists, career staff scientists, postdocs, graduate students and support staff dedicated to cancer research. Our significant contributions to the prevention and cure of cancer are based in compassion for our patients, an emphasis on collaboration, and a culture of scientific excellence.
Moffitt’s size, its singular focus on cancer, and its close interaction and outreach with academic partners and caregivers throughout the state, nation, and world all contribute to the rich, collegial, and collaborative environment required to perform outstanding cancer research and educate the next generation.
Moffitt’s five multidisciplinary research programs consist of integrative teams working together to tackle the complexity of cancer:
- Cancer Biology and EvolutionExit Disclaimer, an innovative program that emerged from systematic in-house collaborations of mathematicians, evolutionary biologists, and basic and clinical cancer researchers.
- Cancer EpidemiologyExit Disclaimer, which contributes to reducing cases of cancer through research to identify risk factors across the cancer continuum comprising etiology, progression, and outcome, and the translation of that knowledge into successful prevention and early detection interventions.
- Chemical Biology and Molecular MedicineExit Disclaimer, which integrates chemical biology and systems biology technologies to develop new therapeutic approaches for the treatment of cancer.
- Health Outcomes and BehaviorExit Disclaimer, which contributes to the prevention, detection, and control of cancer through the study of health-related behaviors, health care practices, and health-related quality of life.
- ImmunologyExit Disclaimer, which develops and delivers advanced clinical immunotherapies to benefit cancer patients. The goal is achieved through close integration of basic, translational and clinical researchers to discover basic mechanisms and rapidly translate them from the bench to the bedside.
Moffitt is also a founding member of the Oncology Research Information Exchange Network (ORIEN), a unique research partnership among North America’s top cancer centers that recognize that collaboration and access to data are the keys to cancer discovery. ORIEN partners utilize a standard system for tracking patient molecular, clinical, and epidemiological data and follows the patient throughout his or her lifetime.
- This profile was provided by the Moffitt Cancer Center.
